clinical

Not two months after the Swiss start-up Cytos's experimental anti-smoking vaccine failed in a mid-stage study, Nabi Biopharmaceuticals (NABI) and GlaxoSmithKline (GSK) have signed a licensing agreement for Nabi's own anti-smoking vaccine, NicVAX. The deal, which could potentially be worth more than...

Back in early July, Human Genome Sciences Inc. (HGSI) shares jumped over 230 percent in one day after the pharmaceutical company said its experimental lupus drug had succeeded in a late-stage clinical trial, silencing many of its skeptics. If you decided then that a 230 percent move was all that...